Search Page

1

Cite

Share

Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody.

Boyles JS, Beidler CB, Strifler BA, Girard DS, Druzina Z, Durbin JD, Swearingen ML, Lee LN, Kikly K, Chintharlapalli S, Witcher DR. Boyles JS, et al. Among authors: witcher dr. MAbs. 2020 Jan-Dec;12(1):1831880. doi: 10.1080/19420862.2020.1831880. MAbs. 2020. PMID: 33183151 Free PMC article.

Cite

Share

2

Cite

Share

Ghrelin in obesity.

Heiman ML, Witcher DR. Heiman ML, et al. Among authors: witcher dr. Metab Syndr Relat Disord. 2006 Spring;4(1):37-42. doi: 10.1089/met.2006.4.37. Metab Syndr Relat Disord. 2006. PMID: 18370769

Cite

Share

3

Cite

Share

Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.

Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR. Sheetz M, et al. Among authors: witcher dr. Br J Clin Pharmacol. 2019 May;85(5):935-948. doi: 10.1111/bcp.13877. Epub 2019 Mar 4. Br J Clin Pharmacol. 2019. PMID: 30677788 Free PMC article. Clinical Trial.

Cite

Share

4

Cite

Share

Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.

Datta-Mannan A, Estwick S, Zhou C, Choi H, Douglass NE, Witcher DR, Lu J, Beidler C, Millican R. Datta-Mannan A, et al. Among authors: witcher dr. MAbs. 2020 Jan 1;12(1):1770028. doi: 10.1080/19420862.2020.1770028. MAbs. 2020. PMID: 32486889 Free PMC article.

Cite

Share

5

Cite

Share

Role of TGF-alpha in the progression of diabetic kidney disease.

Heuer JG, Harlan SM, Yang DD, Jaqua DL, Boyles JS, Wilson JM, Heinz-Taheny KM, Sullivan JM, Wei T, Qian HR, Witcher DR, Breyer MD. Heuer JG, et al. Among authors: witcher dr. Am J Physiol Renal Physiol. 2017 Jun 1;312(6):F951-F962. doi: 10.1152/ajprenal.00443.2016. Epub 2017 Mar 1. Am J Physiol Renal Physiol. 2017. PMID: 28249836 Free article.

Cite

Share

6

Cite

Share

Validation of a de-immunization strategy for monoclonal antibodies using cynomolgus macaque as a surrogate for human.

Kovalova N, Boyles J, Wen Y, Witcher DR, Brown-Augsburger PL, Wroblewski VJ, Chlewicki LK. Kovalova N, et al. Among authors: witcher dr. Biopharm Drug Dispos. 2020 Mar;41(3):111-125. doi: 10.1002/bdd.2222. Epub 2020 Mar 10. Biopharm Drug Dispos. 2020. PMID: 32080869

Cite

Share

7

Cite

Share

Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.

Kelly RM, Kowle RL, Lian Z, Strifler BA, Witcher DR, Parekh BS, Wang T, Frye CC. Kelly RM, et al. Among authors: witcher dr. Biotechnol Bioeng. 2018 Mar;115(3):705-718. doi: 10.1002/bit.26496. Epub 2017 Dec 1. Biotechnol Bioeng. 2018. PMID: 29150961

Cite

Share

8

Cite

Share

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Alakhras NS, Qiu J, Rocha GV, Witcher DR, Koester A, You J, Schaer DA, Holmgaard RB, Driscoll K, Willy JA, Malherbe LP. Alakhras NS, et al. Among authors: witcher dr. MAbs. 2018 Aug/Sep;10(6):913-921. doi: 10.1080/19420862.2018.1474996. Epub 2018 Jul 26. MAbs. 2018. PMID: 29953319 Free PMC article.

Cite

Share

9

Cite

Share

Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.

Datta-Mannan A, Boyles J, Huang L, Jin ZY, Peariso A, Murphy AT, Ellis B, Douglass N, Norouziyan-Cooper F, Witcher DR. Datta-Mannan A, et al. Among authors: witcher dr. Biotechnol J. 2019 Mar;14(3):e1800007. doi: 10.1002/biot.201800007. Epub 2018 Jun 26. Biotechnol J. 2019. PMID: 29802766

Cite

Share

10

Cite

Share

Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody.

Boyles JS, Atwell S, Druzina Z, Heuer JG, Witcher DR. Boyles JS, et al. Among authors: witcher dr. Protein Sci. 2016 Nov;25(11):2028-2036. doi: 10.1002/pro.3023. Epub 2016 Sep 9. Protein Sci. 2016. PMID: 27543934 Free PMC article.

Cite

Share